

(19)



Eur päisch s Patentamt
European Patent Office
Offic européen d s brevets



(11)

EP 1 066 830 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
10.01.2001 Bulletin 2001/02

(51) Int Cl.7: **A61K 31/00, A61K 31/549,**
A61K 45/06, A61P 35/00

(21) Application number: **00304737.0**

(22) Date of filing: **05.06.2000**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **04.06.1999 US 137421 P**
27.08.1999 US 151050 P
29.11.1999 US 167681 P
05.01.2000 US 174607 P
14.02.2000 US 182200 P

(71) Applicant: **ED. GEISTLICH SÖHNE AG FÜR**
CHEMISCHE INDUSTRIE
6110 Wolhusen (CH)

(72) Inventors:
• **Stendel, Rudiger c/o B. Franklin University Clinic**
12200 Berlin (DE)
• **Pfarrmann, Rolf Wilhelm**
6006 Luzern (CH)

(74) Representative: **Pett, Christopher Phineas**
Frank B. Dehn & Co.,
European Patent Attorneys,
179 Queen Victoria Street
London EC4V 4EL (GB)

(54) **Uses and compositions for treating primary and secondary tumors of the central nervous system (cns)**

(57) Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a

bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantation methods and angiographic methods.

EP 1 066 830 A2

D scriptl n

[0001] The present invention is in the field of treating tumors of the central nervous system (CNS).

5 Description of the Background Art.

[0002] Taurolidine (Bis-(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)methane) was developed by Geistlich Pharma. It is a white crystalline substance, water soluble up to 2%. It is made up of two molecules of taurinamid and three molecules of formaldehyde forming a two-ringed structure bridged by a methylene group.

10 [0003] Taurolidine has primarily an antibiotic and anti-endotoxin effect. It acts by a chemical reaction, so no micro-organism resistance has been observed as yet. This effect of taurolidine is mediated by its active metabolites, which are donors of active methylol-groups: Methylol-Taurultam and Methylol-Taurinamide. The active methylol groups inactivate by reacting with the cell wall of bacteria and with the primary amino groups of endotoxins.

15 [0004] Additional effects of taurolidine were reported in the past: inhibition of TNF and IL-1Beta in mononuclear cells (Bedrosian 1991), inhibition of Tumor Necrosis Factor Toxicity, and inhibition of Peritoneal Tumor Cell Growth in Laparoscopic Surgery (Jacobi 1997).

[0005] Taurolidine solutions have been used as instillation or rinsing solutions of the abdominal cavity in cases of peritonitis. In post-operative instillations, conscious patients have reported as a side-effect irritation of the nerves of the peritoneum, and sometimes strong burning sensations which require intravenous administration of pain killers or anaesthesia.

20 [0006] Monson et al. PCT International Publication Number WO 92/00743 discloses a selective direct inhibiting effect of Taurolidine and/or Taurultam on certain body tumors. (Monson JRT, Ramsey PS, Donohue JH. Preliminary evidence that taurolidine is antineoplastic as well as anti-endotoxin and anti-microbial. Abstract. Br J Surg 77(6) 1990, A711) on B16 melanoma cells and Meth A sarcoma cells in a mice model in vivo, and on fibroblastic tumor cells, LS174T (colon-) carcinoma cells and Jurkat (leukemic-) cells in vitro (International Patent PCT No. PCT/EP91/01269, International Publication Number WO 92/00743 PCT "Use of Taurolidine and/or Taurultam for the treatment of tumors"). However, primary tumors of the brain and medulla of the Central Nervous System (CNS) are very different from those of the body. Nerve cells differ significantly from cells of other organs, and have a much more complex construction. Nerv

25 cells are characterized by a great number of branches which serve to transmit impulses and sensations, including dendrites for reception of impulses, and neurites or axons for emission of impulses. Neuroglia are glia-cells which are present in greater numbers than neurons, and render stability to the nerve cells. Glia-cells are responsible for metabolism and protection of sensitive nerve cells. The cells from which CNS tumors arise have a different metabolism as compared to other tumor cells. Metastases of CNS tumors outside the nervous system are very rare. Effective surgical treatment is often impossible since the tumors are located in functionally important areas, or spread diffusely.

30 [0007] Primary tumors of the brain and spinal cord arise from the different cell types of the CNS. These cell types are neurons, which are responsible for the neuronal function and the glial cells, which have supporting and nutritioning functions. According to the different subtypes of glial and neuronal cells, there are different types of CNS-tumors. The most common brain tumors arise from the glial cells. Various sub-types (astrocytoma, oligodendroglioma, ependymoma, etc.) are encompassed by the term "glioma".

40 [0008] Gliomas are the most common primary brain tumors. The incidence of gliomas is about 5/100,000 persons per year. More than 50% are glioblastoma, the most malignant form, which is responsible for more than 2.5% of the total tumor associated mortality. More than 95% of the patients die within 2 years following diagnosis despite aggressive therapy including surgery, radiotherapy and chemotherapy.

45 [0009] Brain tumors have some special characteristics as compared to "peripheral" tumors. They act as space occupying lesions, caused by the bony skull. This situation causes herniation and death when the tumor grows larger than can be accommodated. Furthermore, primary brain tumors often metastasize via the cerebrospinal fluid within the whole central nervous system. The brain tumor cells have a lower cohesion within the cell formation as compared to "peripheral" tumor cells (Jänisch W.: Pathologie der Geschwülste des Zentralnervensystems In: Klinische Neuropathologie, J. Cervós-Navarro and R. Ferszt (Eds.) Thieme, Stuttgart, New York, 1989). In addition, the metabolism of brain tumors are influenced by the blood/brain barrier.

50 [0010] Both types of tumors, glial and neuronal, can develop malignantly. Malignant gliomas are more frequent as compared to benign gliomas (85% vs. 15%). In the U.S. there are about 20,000 new glioma and medulloblastoma cases per year. The glioblastoma is most common (about 65% among astrocytoma).

55 [0011] The therapeutic options of primary CNS-tumors include surgery, radiotherapy and chemotherapy. Complete resection is often impossible because of poorly defined tumor borders and location within the brain area. Nearly all malignant glioma reoccur within months, 90% on the original site. Reoperation for a recurrent glioma typically extends survival by about 36 weeks (10 weeks with good quality of life). There is no well designed study regarding the beneficial effect of radiotherapy following glioma surgery. In patients older than 65 years, the median survival following tumor

biopsy plus radiation is about 17 weeks, and following tumor removal plus radiation about 30 weeks (the peak incidence of glioblastoma is at an age of about 60 years). However, complete tumor removal plus radiotherapy is considered the reference standard in glioma therapy.

[0012] Chemotherapy using alkylating agents has a positive response rate of about 30%. A positive response generally extends the survival by 6-8 weeks. However, only about 50% of the patients treated with chemotherapy using alkylating agents are able to maintain regular activities.

[0013] Despite progress in diagnosis and treatment, the prognosis of patients with malignant primary CNS-tumors is still poor. The median survival of glioblastoma patients following optimal therapy including complete extirpation and radiation is less than about 10 months (about 1.6 years in grade III astrocytomas). The 1-year survival rate of patients with glioblastoma is about 35%, the 2-year survival rate about 8%.

[0014] Some primary malignant central nervous system tumors cannot be treated surgically because of their location or diffuse extension (gliomatosis, diffuse brain stem gliomas). Chemotherapy is not generally recommended, since the response rate on these alkylating agents (BCNU, CCNU, Procarbazine) is about 10% of patients (data from Greenberg MS. Handbook of Neurosurgery. Third edition 1994, Greenberg Graphics Inc., Lakeland, FL, USA). Heretofore, no therapy could be offered to those patients despite a palliative radiation. Thus, the therapy of primary malignant tumors of the central nervous system has been very unsatisfactory.

[0015] There remains a need in the art for new methods and compositions for treating tumors of the central nervous system.

SUMMARY OF THE INVENTION

[0016] The present invention relates to the use of methylol transfer agents, including Taurolidine and/or Taurultam, for the treatment of tumors of the central nervous system in mammals. Despite the irritation of the nerves of the peritoneum and strong burning sensations which have been side-effects of peritonitis post-operative instillations of Taurolidine; it surprisingly has been found that CNS nerve cells, including the particularly sensitive stem cells of embryonic meningeal cells, remain unaffected following administration of Taurolidine/Taurultam solutions.

[0017] It was surprising to demonstrate a direct antineoplastic effect of Taurolidine and/or Taurultam on neuronal and glial tumor cell lines. This effect was very unexpected due to the quite different behavior of brain tumor cells as compared to other tumor cells, particularly concerning their response to chemotherapeutic agents. Furthermore, the antineoplastic effect of Taurolidine and/or Taurultam was thought only to be associated with the influence on cell adhesion molecules, which explains the prevention of metastatic tumor growth following endoscopic abdominal tumor surgery. A direct antineoplastic effect on brain tumor cells was very unexpected.

DETAILED DESCRIPTION OF THE INVENTION

[0018] Taurolidine and Taurultam, its intermediate and active metabolite, are methylol transfer agents. They act by transferring methylol groups at the site of action. Both substances have low toxicity and are not cytotoxic against normal cells.

[0019] This invention provides for medicaments for the treatment and/or prophylaxis of tumours and/or suppressing of primary and secondary tumors of the central nervous system in mammalian subjects which contain an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam for administration to a mammalian subject suffering from or at risk of central nervous system tumor growth. Furthermore the invention includes special methods for local application of Taurolidine and/or Taurultam in solution using microdialysis methods, irrigation methods, implantation methods, and angiographic methods. The terms Taurolidine and/or Taurultam as used herein are intended to refer to the compounds Taurolidine, Taurultam, Taurultam-glucose (as described below), and their substantial bioequivalents or agents which act in a substantially similar manner. For example, an aminoglycan derived from Taurultam and any other suitable derivative of Taurolidine and/or Taurultam, or agents which act in a substantially similar manner, can be utilized like Taurolidine and/or Taurultam according to the invention.

[0020] The term "treatment" as used herein is intended to refer to treatment, prophylaxis and/or suppression of CNS tumors. The present invention is applicable to treatment of CNS tumors, which may include:

- Glioblastoma Multiforme (GBM)
- High grade gliomas
- Anaplastic oligodendroglioma
- Low grade gliomas
- Recurrent malignant gliomas
- Anaplastic astrocytoma
- Advanced metastatic melanoma

- Recurrent high grade primary brain tumors
- Primary central nervous system lymphoma
- Leptomeningeal dissemination of malignant glioma (meningeal gliomatosis).

[0021] Treatment takes place primarily in connection with surgical intervention, such as surgical removal of a CNS tumor, as well as postoperative local application of taurolidine and/or Taurultam solution while using, for example, a microdialysis method or an irrigation method. Since the blood/brain barrier is passed by Taurolidine and/or Taurultam, it also may be appropriate to administer 2% taurolidine solutions or 3% Taurultam solutions intravenously through a central catheter. Here, in addition to the antineoplastic action, prevention of infection is also of great advantage for the patient. In this connection, dosage appropriately may be 15-20 g of taurolidine as a 2% solution through a central catheter daily for 7-8 days, or alternatively as 3% Taurultam solution, 20-30 g Taurultam daily, for 7-8 days with adults. This is intended to preserve or improve neurological function and health-related quality of life. For local application in connection with operations in the brain, glucose-based solutions, with or without electrolytes, and which additionally contain 0.2-1% Taurolidine, Taurultam or Taurultam-glucose, are preferred.

[0022] Basic treatment solutions preferably are modeled after cerebrospinal solution, contain glucose and electrolytes, are substantially isotonic to the extent possible and have a slightly alkaline pH value of about 7.3-7.35. The following ingredients may be included in a basic solution:

- Bicarbonate
- Sodium
- Potassium
- Calcium
- Magnesium
- Lactate
- Chloride
- Glucose

Taurolidine, Taurultam, Taurultam-glucose or the like are added to a basic solution.

Exemplary Basic Solution

[0023] A basic solution may, for example, be comprised of Cerebrospinal Fluid (CSF) components as shown in the following table.

CONSTITUENT	UNITS	CSF	PLASMA	CSF: plasma ratio
osmolarity	mOsm/L	295	295	1.0
H ₂ O content		99 %	93%	
sodium	mEq/L	138	138	1.0
potassium	mEq/L	2.8	4.5	0.6
chloride	mEq/L	119	102	1.2
calcium	mEq/L	2.1	4.8	0.4
pCO ₂	mm HG	47	41	1.1
pH		7.33	7.41	
pO ₂	mm Hg	43	104	0.4
glucose	mg/dl	60	90	0.67
lactate	mEq/L	1.6	1.0	1.6

Exemplary Amino-sugar/Taurultam-glucose Treatment Agent

[0024] 13.6 g Taurultam and 18 g of anhydrous glucose were weighed out into a 250 ml serum bottle, and 200 ml of distilled water were added. The solution obtained was heated to 100°C for 30 minutes. The clear solution was evaporated in a vacuum until dry. The residue was absorbed in 96% alcohol and placed in an Erlenmeyer flask overnight

EP 1 066 830 A2

for forming crystals.

[0025] Amino-sugar/Taurultam-glucose crystallized out, and the crystals were suction filtered with a raw yield of 5.3 g.

[0026] From alcohol mixed with a few drops of water, white crystals were recrystallized:

Melting point	168° - 170° C.			
Calculated	C = 36.23	H = 6.03	N = 9.39	S = 10.74%
Found	C = 36.26	H = 6.10	N = 9.09	S = 10.90%

The IR spectrum corresponded NMR in DMSO₆ 200 MHZ. Sulfonamide NH coupling to its adjacent CH₂, one OH coupling to CH₂ and three OH's couplings to CH indicated internal loss of water and that the chain had cyclised to form a sugar.

Solutions for use in the irrigation and/or microdialysis methods

[0027]

Solution 1	1000 ml contain:
Glucose monohydrate for injection purposes	27.500 g
Sodium	3.382 g
Potassium	0.157 g
Ca ⁺⁺	0.009 g
Cl ⁻	5.520 g
Taurultam	0.5%

The solution is slightly hypertonic.

The glucose can be replaced by 25 g levulose (fructose).

The solution is then insulin-independent.

Solution 2	1000 ml contain:
Sodium	3.151 g
Potassium	0.156 g
Ca ⁺⁺	0.066 g
Mg ⁺⁺	0.033 g
Cl ⁻	3.900 g
Acetate	2.173 g
Taurultam-glucose	0.5%

The pH value is set at pH 7.3.

The solutions 1 and 2 are filtered in an appropriately sterile manner with a 0.1 micron sterile filter and aseptically deposited in sterile infusion bottles.

Solution 3	1000 ml contain
Glucose monohydrate for injection purposes	18.330 g
Sodium lactate	2.460 g
Sodium chloride	2.800 g
Potassium chloride	0.187 g
Calcium chloride 2 H ₂ O	0.147 g
Magnesium chloride 6 H ₂ O	0.152 g
Taurolidine	1%

The pH is set at 7.3. The solution is filtered in a sterile manner and aseptically deposited in 100 ml infusion bottles.

Solution 4	1000 ml contain:
Sodium chloride	4.000 g
Potassium chloride	0.050 g
Calcium chloride 2 H ₂ O	0.066 g
Sodium hydrogen carbonate	0.050 g
Taurultam	1%

The solution is set at a pH of 7.5 prior to sterilization and subsequently filtered in a sterile manner, deposited in 250 ml infusion bottles and sterilized with steam for 15 minutes at 121° C.

Exemplary Treatment Modalities

[0028] Taurolidine and/or Taurultam may be administered by injection or infusion, or by local application. Isotonic glucose solution and/or artificial cerebrospinal fluid solution as described above may be used containing Taurolidine and/or Taurultam, or a substantial bioequivalent thereof. The local administration can be performed via (a) microdialysis using a probe tube, and (b) direct irrigation and/or implantation of a catheter, and single or repeated irrigation. A Microdialysis-method can be utilized in nonextirpated tumors or reoccurrences as well as in inoperable tumors, e.g., diffuse brain stem gliomas. An irrigation/catheter method may be utilized following complete or incomplete tumor extirpation.

a) Microdialysis Method

[0029] An isotonic solution as described above, is stored at body temperature in a tank. A small pump (subcutaneous or outside the body) forces the Taurolidine and/or Taurultam solution via tubular microprobe to the tumor and/or its surrounding. The microprobe may be formed of plastic material with a small lumen. The tip of the probe may have a semipermeable membrane so that an osmotic fluid exchange can occur. In this way, the Taurolidine and/or Taurultam can diffuse inside the tumor and its surroundings. Different types of probes can include a probe with a small tip to terminate directly inside the tumor. With large tumors, a large membrane can be provided at the end of the probe to lie inside the tumor cavity or on the surface of the tumor. In some cases with large tumors, it may be necessary to implant more than one probe.

b) Irrigation/Catheter Method

[0030] Following removal of a tumor, or with cystic tumors, direct single or repeated irrigation of the tumor cavity or area may be performed. Furthermore, a catheter can be implanted in the tumor cavity for repeated local administration with Taurolidine and/or Taurultam.

c) Angiographic Method

[0031] Another method for regional application of Taurolidine and/or Taurultam may be provided for tumors with blood supply by one or a few dominant feeder arteries. Taurolidine and/or Taurultam may be administered by an angiographic catheter, which may be introduced supraselectively into the feeders. The Taurolidine and/or Taurultam then may be administered once or repeatedly.

d) Implantation Method

[0032] Following complete or incomplete removal of a tumor, direct single or repeated implantation of a matrix containing Taurolidine and/or Taurultam into the tumor cavity may be performed.

Results

[0033] Taurolidine and/or Taurultam have been found to inhibit directly the growth of CNS tumor cell lines, including neuronal (HT22) as well as glial (C6) tumor cell lines. Furthermore, this action was shown to be selective in that the growth of primary cell lines of a fetal rat central nervous system required significantly higher concentrations and a significantly, longer contact time for inhibition, as compared to tumor cells (taking into account a very high general sensitivity of primary cell lines of the fetal rat central nervous system). The effect was concentration-dependent. Anti-

neoplastic effects of concentrations of 0.1 to 4 mg/ml Taurolidine and/or Taurultam in PVP and glucose solution was demonstrated. The tumor cells were inhibited starting after 10 minutes. Following about 1 to 2 hours 90% of the tumor cells were inhibited.

5 Summary

[0034] The tumor-inhibiting agents of the present invention, including Taurolidine and/or Taurultam, may be administered by injection or infusion. Agents in accordance with the present invention may be administered locally using microdialysis utilizing probes, as well as regionally using superselective angiographic catheters with continuous or sequential administration of an agent in accordance with the present invention.

[0035] Probes for practicing a microdialysis method in accordance with the invention can be placed using neuronavigation, MRI guidance and/or ultrasound guidance. A diagnostic biopsy can be taken from the tumor to make a histological diagnosis during the same surgical procedure in which treatment utilizing a microdialysis method in accordance with the invention is utilized. Alternatively, during a microdialysis method in accordance with the present invention, fluid can be obtained from the tumor or its surroundings so as to maintain a desired fluid level in the area of the tumor.

[0036] An agent in accordance with the present invention can be administered by a permanently or temporarily implanted catheter for continuous or repeated local irrigation of a tumor or its surroundings. The treatment agent can be administered locally by irrigation of the surroundings of a totally or partially extirpated tumor.

[0037] In preferred embodiments, Taurolidine and/or Taurultam is administered intravenously in a dosage range of about 50-500mg/kg per day, sequentially or by continuous administration.

[0038] Separately or simultaneously with administration of a methylol transfer agent in accordance with the present invention, other agents can be administered to the patient, including cytotoxic, antineoplastic agents (including alkylating agents, and/or agents involved in tumor metabolism). Alternatively or additionally, if desired, other tumor treating agents may be administered, such as interleukin-1, interleukin-2, interferon, or other immunomodulating agents.

[0039] The advantages of combination therapy include:

- 1) Synergic effects may be realized from employment of a combination therapy with regard to achievement of tumor control and survival improvement.
- 2) Dosage reduction in administration of antineoplastic medicaments will lead to amelioration of the considerable side effects, such as hair loss, nausea, vomiting, diarrhea, etc.
- 3) Combination therapy allows for different ways of application of the medicaments, e.g., local Taurolidine/Taurultam administration, systemic general chemotherapy, etc.

[0040] Taurolidine and/or Taurultam can be administered by intraperitoneal application in combination with local intrathecal or intravenous general chemotherapy.

[0041] This combined administration facilitates prevention of development of metastases and dissemination thereof into the liquor and into the brain during laparotomy or laparoscopic tumor surgery.

40 Example 1

[0042] Taurolidine and Taurultam have been found to inhibit directly the growth of neuronal (HT22, mouse), glial (C6, rat), and mixed neuronal and glial (U373, human) tumor cell lines. For the latter cell line, however, the experiments are not complete as yet. Furthermore, this action was shown to be selective in that the growth of normal central nervous system cells was not significantly inhibited. The effect was concentration-dependent. Antineoplastic effects of concentrations of 0.1 to 4 mg/ml Taurolidine and/or Taurultam was demonstrated. The tumor cells were inhibited selectively beginning after 30 minutes. Following 1 to 3 hours about 90% of the tumor cells were inhibited. For the cell culture, cells were used in RPMI 1640 medium and plated in Falcon flasks. Following incubation with 0.1 - 4 mg/ml Taurolidine and Taurultam, cytological changes were recorded after 10, 30, 60, 120, 180, 300 minutes, and after 24 and 48 hours.

[0043] Beginning following 30 minutes, cytological changes were observed, including: (a) development of vacuoles, and (b) condensation of nuclei, shrinking of cytoplasm, and cell death.

[0044] Ultrastructural changes include: swelling of mitochondria, swelling of nuclei, swelling of cytoplasm, and rupture of cell membrane. The first changes occurred after 10 minutes, increasing with time and concentration.

[0045] The results of DNA-FACS supported the cytological and ultrastructural observations.

[0046] The effect of taurolidine/taurultam on primary CNS-cells was investigated using the brain cells of rat fetuses in a cell culture. We found no significant cytological effect following 48 hours.

[0047] For treatment of glioma patients, Taurolidine and/or Taurultam may be administered by injection or infusion, or by local application. The local administration can be performed via (a) microdialysis using tubular probes, and (b)

direct irrigation and/or implantation of a temporary or permanent catheter, and single or repeated irrigation.

[0048] The Microdialysis-method can be utilized in nonextirpated tumors or reoccurrences as well as in inoperable tumors, e.g., diffuse brain stem gliomas. The irrigation/catheter method may be utilize following complete or incomplete tumor extirpation.

Example 2

COMBINED THERAPY WITH TAUROLIDINE AND ADDITIONALLY ANTINEOPLASATIC AGENTS IN PATIENTS WITH GLIOBLASTOMA, GLIOSARCOMA, ANAPLASATIC GLIOMA AND ASTROCYTOMA

[0049] The combination of Taurolidine/Taurultam with antineoplastic agents for treatment of brain tumors such as glioblastoma, astrocytoma and gliosarcoma offers a number of advantages.

[0050] The combination of, for example, alkylated agents and Taurolidine and/or Taurultam avoids or reduces side effects such as nausea, vomiting, diarrhea, etc., induced by use of antineoplastic medicaments. The dosage of these antineoplastic medicaments can be reduced by up to half or more and still increase the overall response rate (disease stabilization rate) by synergic effects.

[0051] Radiotherapy with its strong side effects can also be avoided or reduced in many cases.

[0052] The recurrence rate of dissemination of tumors in primary brain tumors in glioblastoma multiforma and astrocytoma can also be reduced by a combined therapy.

[0053] Of various antineoplastic agents, those medicaments should be chosen which, due to their molecular structure, are unlikely to interact with Taurolidine and/or Taurultam. It is also preferable to direct the combined chemotherapy at the tumor in different ways, e.g., locally to the brain tumor via direct irrigation of Taurolidine and/or Taurultam, or by implantation of a permanent catheter, or via microdialysis in using tubes, and by established chemotherapy i.v. or orally, e.g. by administration of Temozolamide 100 mg/m² once daily for 5 days.

[0054] Alternatively, after surgical resection of glioblastoma, localized and sustained delivery of 5-fluorouracil (f-FU) can be provided in combination with Taurolidine and/or Taurultam via central catheter as drop infusion for several days.

[0055] In cases of laparoscopic emergency surgery of tumors, laparoscopic cholecystectomy, cholecystitis, laparoscopic cholecystectomy, etc. in tumor patients as well as in general laparotomy, the intraperitoneal administration of 2% Taurolidine as lavage or instillation in combination with regular i.v. chemotherapy for combating tumors, prevention of metastases and dissemination in the brain, is possible.

[0056] In leptomeningeal dissemination of malignant glioma (meningeal gliomatosis) associated with poor survival intrathecal (IT) chemotherapeutic agents used in combination with local or systemic administration of Taurolidine and/or Taurultam solutions to achieve tumor control and improve survival, may be helpful.

[0057] The following antineoplastic agents may be compatible for combination with Taurolidine and/or Taurultam:

PCV-Chemotherapy: Combination of:

- procarbazine HCl
- lomustine (CCNU) (CeeNu)
- vincristine sulfate

Cisplatin
Methotrexate
Cytosinarabioside (ara-C) cytarabine hydrochlorid
Temozolamide
MX2-hydrochloride
Topotecan
Paclitaxel (Taxol)

Interleukin-2 (IL-2) in simultaneous administration of Interleukin-1 (IL-1) and lymphokine-activated killer-cell or TNF, a combination with Taurolidine leads to reduction of toxicity of the cytokines and is more agreeable to the patient.

[0058] The nitrosourea medicaments such as ACNU/BCNU/CCNU are generally applied in lower concentration, e.g., 30-50mg/m² i.v. once per week of 6 weeks. Temozolamid is given orally in a dosage of 50-100mg/m² for 5 days. MX-2-hydrochlorid is given as intravenous bolus at 20mg/m² every 28th day for several months until progression occurs.

[0059] As another choice, further antineoplastic medicaments are suitable for combination:

Cyclophosphamid approximately 150 mg/m²
 Fluorouracil (5-FU) 40 mg/m² as local bolus

or in the form of microspheres as intrathecal (IT) -chemotherapy

Doxorubicin 10-15 mg/m² i.v.

Hydroxycarbamide

[0060] Cytosinarabinosides (ara-C), thiotriethylene-phosphoramidate (thio-TEPA), and Neocarzinostatis can be administered in low doses in IT-chemotherapy in various combinations with Taurolidine and/or Taurultam for improvement of survival and achievement of tumor control and prevention of dissemination, respectively.

Dosage

[0061] The solution for delivery to a patient should contain an effective dosage of Taurolidine and/or Taurultam and/or Taurultam-glucose in the tissue-culture of glioblastoma multiform-tumor cells: as little as 0.1-4 mg/ml Taurolidine inhibits or kills tumor cells in tissue-culture.

[0062] Taurultam so far has been shown to be almost twice as effective as Taurolidine, the explanation of which may be found in the equilibrium of Taurolidine in aqueous solution between Methylol-Taurultam and Taurultam.

[0063] Taurultam-glucose, on the other hand, has to be dosaged about twice as high as Taurultam, as the molecular weight from Taurultam increases from 136 to 298.

[0064] When administered to patients utilizing the irrigation/catheter method described above, a concentration of at least about 4 mg/ml Taurolidine, Taurultam or Taurultam-glucose, respectively, should be utilized.

Claims

1. Use of a tumour-inhibiting methylol transfer agent in the preparation of a medicament for the treatment of tumours of the central nervous system.
2. Use as claimed in claim 1 wherein the agent is taurolidine, taurultam, taurultam-glucose or a mixture thereof.
3. Use as claimed in claim 1 or claim 2 wherein the medicament is adapted for administration by injection or infusion.
4. Use as claimed in claim 1 or claim 2 wherein the medicament is adapted for administration by a probe using microdialysis.
5. Use as claimed in any of claims 1 to 4 wherein the medicament comprises an isotonic solution of the agent.
6. Use as claimed in any of claims 1 to 5 wherein the tumor to be treated is a glioma, glioblastoma, astrocytoma, ependymoma, plexus carcinoma, plexus papilloma, medulloblastoma, neuroblastoma, ganglioglioma, ganglioneuroma, pineoblastoma, malignant menigeoma, gliomatosis cerebri, teratoma of the pineal gland, retinoblastoma or mixed-cell-tumor.
7. Use as claimed in any of claims 1 to 6 wherein the medicament further contains a cytotoxic antineoplastic agent, an alkylating agent or a tumour metabolism agent.
8. Use as claimed in any of claims 1 to 6 wherein the medicament further contains an immunomodulating agent such as interleukin-1, interleukin-2 or interferon.
9. Use as claimed in any of claims 1 to 8 wherein the medicament is in the form of a matrix adapted for application to a tumour cavity.
10. A pharmaceutical composition comprising a methylol transfer agent and at least one antineoplastic agent, immunomodulating agent or central nervous system tumor metabolism agent, optionally in association with a pharmaceutically accepted carrier, diluent or excipient, for administration to a mammal at risk of central nervous system tumor growth.

EP 1 066 830 A2

11. The composition of claim 11, wherein said agent is Taurolidine, Taurultam or a mixture thereof.

12. The composition of claim 11, wherein said agent is Taurultam-glucose.

5 13. A composition as claimed in claim 10 in the form of a two-part kit, one part comprising the methylol transfer agent and the other part an antineoplastic agent, immunomodulating agent or central nervous system tumor metabolism agent, with instructions for combination therapy.

10

15

20

25

30

35

40

45

50

55

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 066 830 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
16.10.2002 Bulletin 2002/42

(51) Int Cl.7: **A61K 31/00**, A61K 31/549,
A61K 45/06, A61P 35/00

(43) Date of publication A2:
10.01.2001 Bulletin 2001/02

(21) Application number: **00304737.0**

(22) Date of filing: **05.06.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **04.06.1999 US 137421 P**
27.08.1999 US 151050 P
29.11.1999 US 167681 P
05.01.2000 US 174607 P
14.02.2000 US 182200 P

(71) Applicant: **ED. GEISTLICH SÖHNE AG FÜR
CHEMISCHE INDUSTRIE
6110 Wolhusen (CH)**

(72) Inventors:

- **Stendel, Rudiger**
12247 Berlin (DE)
- **Pfarrmann, Rolf Wilhelm**
6006 Luzern (CH)

(74) Representative: **Pett, Christopher Phineas**
Frank B. Dehn & Co.,
European Patent Attorneys,
179 Queen Victoria Street
London EC4V 4EL (GB)

(54) **Uses and compositions for treating primary and secondary tumors of the central nervous system (cns)**

(57) Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject

suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantation methods and angiographic methods.

EP 1 066 830 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 30 4737

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 92 00743 A (GEISTLICH SOEHNE AG) 23 January 1992 (1992-01-23) * page 2, paragraph 4 - page 3, paragraph 2 * * abstract * * claims 1-10 *	1-5, 7, 8, 10-13	A61K31/00 A61K31/549 A61K45/06 A61P35/00
X	US 5 593 665 A (PFIRRMANN ROLF W ET AL) 14 January 1997 (1997-01-14) * abstract * * column 1, line 28 * * column 1, line 66 - column 2, line 3 * * column 2, line 46 - line 56 * * claim 1 *	1-13	
X	WO 99 06114 A (GEISTLICH SOEHNE AG ; PFIRRMANN ROLF (CH); PETT CHRISTOPHER (GB)) 11 February 1999 (1999-02-11) * claims 1-14 *	1-5, 10-12	
E	WO 01 39762 A (CALABRESI PAUL ; DARNOWSKI JAMES (US); RHODE ISLAND HOSPITAL A LIFE) 7 June 2001 (2001-06-07) * claims 1, 3, 7, 8, 18 *	1-13	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
-/-			
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p style="text-align: center;">see sheet C</p>			
Place of search THE HAGUE		Date of completion of the search 23 August 2002	Examiner Langer, O
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.02 (P04C07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 00 30 4737

Claim(s) searched completely:

2

Claim(s) searched incompletely:

1, 3-13

Reason for the limitation of the search:

Present claims 1 and 3-13 relate to compounds defined by reference to desirable characteristics or properties, namely 'tumour-inhibiting methylol transfer agent(s)', 'cytotoxic antineoplastic agent(s)', 'alkylating agents', '(central nervous system) tumour metabolism agent(s)' or 'immunomodulating agent(s)'.

The claims cover the use of all compounds having this characteristics or properties, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved, namely the inhibition of tumors, cell death, alkylation, control of metabolism and modulation of the immune system.

Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the use of taurolidine, taurultam and taurultam-glucose alone or in combination with the compounds explicitly listed in claim 8 and in the description on pages 13-14.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 30 4737

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
E	WO 01 39763 A (CALABRESI PAUL ;COSTIN JAMES (US); DARNOWSKI JAMES (US); RHODE ISL) 7 June 2001 (2001-06-07) * claims 1,2,6,11,15,18 *	1-13	
T	US 2002/098164 A1 (PFIRRMANN ROLF W ET AL) 25 July 2002 (2002-07-25) * claims 1-5 *	1-13	
T	EP 1 201 247 A (GEISTLICH SOEHNE AG) 2 May 2002 (2002-05-02) * the whole document *	1-13	
T	US 2002/052366 A1 (CALABRESI PAUL ET AL) 2 May 2002 (2002-05-02) * the whole document *	1-13	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 02.02 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 4737

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

23-08-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9200743 A	23-01-1992	WO 9200743 A1	23-01-1992
		EP 0491018 A1	24-06-1992
		JP 5500973 T	25-02-1993
US 5593665 A	14-01-1997	DE 69115263 D1	18-01-1996
		DE 69115263 T2	08-08-1996
		EP 0520021 A1	30-12-1992
		CA 2078221 A1	16-09-1991
		WO 9113628 A1	19-09-1991
		ES 2080307 T3	01-02-1996
WO 9906114 A	11-02-1999	EP 1001781 A2	24-05-2000
		WO 9906114 A2	11-02-1999
		JP 2001511463 T	14-08-2001
WO 0139762 A	07-06-2001	AU 2064901 A	12-06-2001
		AU 2065001 A	12-06-2001
		WO 0139762 A2	07-06-2001
		WO 0139763 A2	07-06-2001
		US 2002052366 A1	02-05-2002
		US 6429224 B1	06-08-2002
		US 2002049200 A1	25-04-2002
WO 0139763 A	07-06-2001	AU 2064901 A	12-06-2001
		AU 2065001 A	12-06-2001
		WO 0139762 A2	07-06-2001
		WO 0139763 A2	07-06-2001
		US 2002052366 A1	02-05-2002
		US 6429224 B1	06-08-2002
		US 2002049200 A1	25-04-2002
US 2002098164 A1	25-07-2002	AU 8155001 A	02-05-2002
		EP 1201247 A2	02-05-2002
EP 1201247 A	02-05-2002	AU 8155001 A	02-05-2002
		EP 1201247 A2	02-05-2002
		US 2002098164 A1	25-07-2002
US 2002052366 A1	02-05-2002	AU 2064901 A	12-06-2001
		AU 2065001 A	12-06-2001
		WO 0139762 A2	07-06-2001
		WO 0139763 A2	07-06-2001
		US 6429224 B1	06-08-2002
		US 2002049200 A1	25-04-2002

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

